The President of Novavax (NVAX) is Buying Shares


Today, the President of Novavax (NVAX), Gregory Glenn, bought shares of NVAX for $5,840.

This recent transaction increases Gregory Glenn’s holding in the company by 1.36% to a total of $488.7K.

See today’s analyst top recommended stocks >>

Currently, Novavax has an average volume of 1.2M.

Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $21.44, reflecting a 272.2% upside. Five different firms, including H.C. Wainwright and Oppenheimer, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts